Tangsathapornpong Auchara, Nanthapisal Sira, Pontan Kanassanan, Bunjoungmanee Pornumpa, Neamkul Yamonbhorn, Boonyarangkul Arthit, Wanpen Supattra, Fukpho Waraphon, Jitpokasem Sumana, Tharabenjasin Phuntila, Jaru-Ampornpan Peera
Department of Pediatrics, Faculty of Medicine, Thammasat University, Khlong Nueang, Khlong Luang, Pathum Thani 12120, Thailand.
Research Unit in Infectious and Immunology, Faculty of Medicine, Thammasat University, Khlong Nueang, Khlong Luang, Pathum Thani 12120, Thailand.
Vaccines (Basel). 2023 Feb 27;11(3):553. doi: 10.3390/vaccines11030553.
The changes in the severe acute respiratory syndrome coronavirus 2 and the tapering of immunity after vaccination have propelled the need for a booster dose vaccine. We aim to evaluate B and T cell immunogenicity and reactogenicity of mRNA-1273 COVID-19 vaccine (100 µg) as a third booster dose after receiving either two doses of inactivated COVID-19 vaccine (CoronaVac) or two doses of viral vector vaccine (AZD1222) in adults not previously infected with COVID-19. The anti-receptor-binding-domain IgG (anti-RBD IgG), surrogate virus neutralization test (sVNT) against the Delta variant, and Interferon-Gamma (IFN-γ) level were measured at baseline, day (D)14 and D90 after vaccination. In D14 and D90, the geometric means of sVNT were significantly increased to 99.4% and 94.5% inhibition in CoronaVac, respectively, whereas AZD1222 showed inhibition of 99.1% and 93%, respectively. Anti-RBD IgG levels were 61,249 to 9235 AU/mL in CoronaVac and 38,777 to 5877 AU/mL in AZD1222 after D14 and D90 vaccination. Increasing median frequencies of S1-specific T cell response by IFN-γ concentration were also elevated in D14 and were not significantly different between CoronaVac (107.8-2035.4 mIU/mL) and AZD1222 (282.5-2001.2 mIU/mL). This study provides evidence for the high immunogenicity of the mRNA-1273 booster after two doses of CoronaVac or AZD1222 in the Thai population.
严重急性呼吸综合征冠状病毒2的变化以及接种疫苗后免疫力的逐渐减弱推动了对加强剂量疫苗的需求。我们旨在评估mRNA-1273新冠疫苗（100μg）作为第三剂加强针的B细胞和T细胞免疫原性及反应原性，该加强针针对的是未曾感染过新冠病毒的成年人，这些成年人之前已接种过两剂灭活新冠疫苗（科兴疫苗）或两剂病毒载体疫苗（AZD1222）。在接种疫苗后的基线、第14天和第90天测量抗受体结合域IgG（抗RBD IgG）、针对德尔塔变体的替代病毒中和试验（sVNT）以及干扰素-γ（IFN-γ）水平。在第14天和第90天，科兴疫苗组sVNT的几何均值分别显著提高至抑制率99.4%和94.5%，而AZD1222组的抑制率分别为99.1%和93%。接种疫苗后第14天和第90天，科兴疫苗组的抗RBD IgG水平为61,249至9235 AU/mL，AZD1222组为38,777至5877 AU/mL。IFN-γ浓度导致的S1特异性T细胞反应的中位频率增加在第14天也有所升高，科兴疫苗组（107.8 - 2035.4 mIU/mL）和AZD1222组（282.5 - 2001.2 mIU/mL）之间无显著差异。本研究为泰国人群中两剂科兴疫苗或AZD1222接种后mRNA-1273加强针的高免疫原性提供了证据。
